Andrew Staron

442 total citations
24 papers, 208 citations indexed

About

Andrew Staron is a scholar working on Molecular Biology, Nephrology and Genetics. According to data from OpenAlex, Andrew Staron has authored 24 papers receiving a total of 208 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 9 papers in Nephrology and 6 papers in Genetics. Recurrent topics in Andrew Staron's work include Amyloidosis: Diagnosis, Treatment, Outcomes (21 papers), Parathyroid Disorders and Treatments (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Andrew Staron is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (21 papers), Parathyroid Disorders and Treatments (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Andrew Staron collaborates with scholars based in United States and Türkiye. Andrew Staron's co-authors include Vaishali Sanchorawala, Lawreen H. Connors, Lisa Mendelson, Gheorghe Doros, J. Mark Sloan, Eric Burks, Frederick L. Ruberg, John C. Lee, Shayna Sarosiek and David Qualls and has published in prestigious journals such as Blood, British Journal of Haematology and American Journal of Transplantation.

In The Last Decade

Andrew Staron

17 papers receiving 199 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Staron United States 7 195 56 50 45 44 24 208
Lisa Mendelson United States 9 199 1.0× 65 1.2× 53 1.1× 46 1.0× 42 1.0× 23 224
Sriram Ravichandran United Kingdom 7 130 0.7× 38 0.7× 32 0.6× 30 0.7× 37 0.8× 24 141
Dina Brauneis United States 10 281 1.4× 44 0.8× 117 2.3× 37 0.8× 59 1.3× 24 298
Brendan Wisniowski Australia 7 119 0.6× 65 1.2× 26 0.5× 30 0.7× 31 0.7× 11 201
Fiona Kwok Australia 6 106 0.5× 17 0.3× 32 0.6× 18 0.4× 36 0.8× 19 124
Terra R. Coakley United States 2 149 0.8× 38 0.7× 10 0.2× 43 1.0× 56 1.3× 2 164
Ludivine Eliahou France 8 115 0.6× 38 0.7× 12 0.2× 21 0.5× 18 0.4× 23 236
Lenka Bauerová Czechia 7 66 0.3× 41 0.7× 5 0.1× 41 0.9× 25 0.6× 11 141
Miguel Munar-Qués Spain 8 232 1.2× 32 0.6× 20 0.4× 17 0.4× 48 1.1× 23 267
Luca Franceschini Italy 6 71 0.4× 20 0.4× 10 0.2× 15 0.3× 23 0.5× 15 144

Countries citing papers authored by Andrew Staron

Since Specialization
Citations

This map shows the geographic impact of Andrew Staron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Staron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Staron more than expected).

Fields of papers citing papers by Andrew Staron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Staron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Staron. The network helps show where Andrew Staron may publish in the future.

Co-authorship network of co-authors of Andrew Staron

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Staron. A scholar is included among the top collaborators of Andrew Staron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Staron. Andrew Staron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Staron, Andrew, Eric Burks, & Vaishali Sanchorawala. (2025). Sustained measurable residual disease (MRD) in light chain amyloidosis: The added value of durability over depth alone. Blood. 146(Supplement 1). 695–695.
3.
Staron, Andrew, et al.. (2024). Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis. British Journal of Haematology. 205(6). 2268–2272. 3 indexed citations
4.
Abdallah, Maya, Adam Lerner, Fabio Petrocca, et al.. (2024). Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Advances. 8(23). 5935–5938. 1 indexed citations
5.
Teodorescu, Patric, et al.. (2024). Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency. Blood. 144(Supplement 1). 4671–4671.
6.
7.
Muchtar, Eli, Morie A. Gertz, Raphael Mwangi, et al.. (2024). Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system. American Journal of Hematology. 99(11). 2118–2126. 1 indexed citations
8.
Anand, Shankara, Andrew Staron, Lisa Mendelson, et al.. (2024). Machine‐learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease. American Journal of Hematology. 99(11). 2140–2151. 4 indexed citations
9.
Staron, Andrew, Eric Burks, Raphaël Szalat, & Vaishali Sanchorawala. (2023). Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab. Blood. 142(Supplement 1). 3405–3405. 1 indexed citations
10.
Gustine, Joshua, Andrew Staron, Lisa Mendelson, et al.. (2023). Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Advances. 7(20). 6080–6091. 9 indexed citations
11.
Li, Julie, et al.. (2023). Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report. Diagnostic Pathology. 18(1). 1–1.
12.
Staron, Andrew, et al.. (2023). Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre. Amyloid. 30(3). 297–302. 2 indexed citations
13.
Staron, Andrew, et al.. (2023). Factors Underlying Impaired Organ Recovery Despite a Deep Hematologic Response in Patients with Systemic AL Amyloidosis. Blood. 142(Supplement 1). 3410–3410. 1 indexed citations
14.
Staron, Andrew, et al.. (2021). Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal. 11(8). 139–139. 73 indexed citations
15.
Staron, Andrew, et al.. (2021). A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis. Blood. 138(Supplement 1). 155–155. 2 indexed citations
16.
Staron, Andrew, et al.. (2020). Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer Journal. 10(11). 118–118. 19 indexed citations
17.
Hughes, David, Andrew Staron, & Vaishali Sanchorawala. (2020). A pharmacist’s review of the treatment of systemic light chain amyloidosis. Journal of Oncology Pharmacy Practice. 27(1). 187–198. 4 indexed citations
18.
Staron, Andrew, Eric Burks, John C. Lee, et al.. (2020). Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Advances. 4(5). 880–884. 38 indexed citations
19.
Qualls, David, Gregory D. Lewis, Vaishali Sanchorawala, & Andrew Staron. (2019). Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. American Journal of Transplantation. 19(11). 3185–3190. 17 indexed citations
20.
Staron, Andrew. (2018). Centered Toward the Margins. 1(2). 142–155. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa Mendelson Breakdown of academic impact, for papers by Sriram Ravichandran Breakdown of academic impact, for papers by Dina Brauneis Breakdown of academic impact, for papers by Brendan Wisniowski Breakdown of academic impact, for papers by Fiona Kwok Breakdown of academic impact, for papers by Terra R. Coakley Breakdown of academic impact, for papers by Ludivine Eliahou Breakdown of academic impact, for papers by Lenka Bauerová Breakdown of academic impact, for papers by Miguel Munar-Qués Breakdown of academic impact, for papers by Luca Franceschini
Rankless by CCL
2026